A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: IW-3300
Drug: Placebo

Registration Number: NCT05188261

Lead Sponsor: Ironwood Pharmaceuticals, Inc.

Brief Summary: This is a first-in-human study to evaluate the safety and tolerability of single ascending doses of IW-3300. The study drug will be administered rectally as a low-volume (20 mL) enema. Study participants will be randomized in a 3:1 ratio to receive a single dose of IW-3300 or placebo. Up to 5 different doses of IW-3300 will be studied. Safety reviews will be conducted before proceeding to each higher dose.

Detailed Description: This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single-ascending-dose study assessing the safety, tolerability, and pharmacokinetics (PK) of IW 3300 administered rectally as a low-volume enema in healthy adult volunteers. This first-in-human study will assess participants for safety, tolerability, and PK.

The study includes up to 6 treatments: placebo and up to 5 dose levels of IW-3300 which will be determined after safety reviews of previous cohorts.

This study will enroll a maximum of 40 participants (up to 5 cohorts of 8 participants each). The 8 participants within each cohort will be randomized in a double-blind manner to receive a single dose of IW-3300 (6 participants) or placebo (2 participants), administered rectally as a low-volume \[20 mL\] enema. Each cohort will progress through a Screening Period, Clinic Period, and Follow-up Period. Treatment duration will be 1 day. Participants will remain in the Phase 1 unit for approximately 24 hours after dosing and will be contacted by phone for follow-up approximately 2 weeks after dosing. Total participation will be 22 to 45 days, including the Screening, Clinic, and Follow-up Periods.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 32

Inclusion Criteria

Males and female subjects of non-childbearing potential
Ages 18 to 60 years
Medically healthy with no clinically significant findings during medical evaluation including physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory tests.
Normal bowel movement frequency of formed stool at baseline (≥3 per week and ≤3 per day; average Bristol stool form scale (BSFS) score of >2 and <6).
Body mass index (BMI) within the range 18.5 to 35.0 kg/m2 (inclusive) at the Screening Visit.
Male subjects and female partners are willing to use double-barrier method of contraception during the study.
If subject is ≥45 years of age, subject is compliant with colorectal cancer screening guidelines according to the American College of Gastroenterology (ACG) Clinical Guidelines: Colorectal Cancer Screening 2021.

Exclusion Criteria

Evidence or history of clinically significant acute or chronic disease, or clinically significant illness within 30 days of the Screening Visit.
History of clinically significant hypersensitivity or allergies to any of the inactive ingredients contained in the active or placebo drug products.
History of any condition that would interfere with their ability to receive an enema, or has had difficulty receiving an enema in the past.
Recent history of anal fissure, anal abscess, complicated hemorrhoids, or presence or history of inflammatory bowel disease.
Used a prescription medication during the 14 days before Check-in
Used any over-the-counter medications, including laxatives, and herbal supplements during the 7 days before Check-in.
Received a licensed or investigational vaccine during the 30 days before Check-in or is planning to receive any vaccine during the study.
Recently received or donated blood products.
Undergone a surgical procedure during the 30 days before Check-in, other than minor dermatologic procedures, or has a history of surgery involving the GI tract or anal canal (with the exception of endoscopic procedures, appendectomy, and cholecystectomy).
Received any investigational drug during the 30 days or 5 half-lives of that investigational drug (whichever is longer) before the Screening Visit, or is planning to receive another investigational drug at any time during the study.
Abnormal laboratory tests or clinically significant findings on safety tests conducted at the Screening Visit or at Check-in.
Confirmed or suspected infection with COVID-19 at the Screening Visit or Check-in.
Positive serology for human immunodeficiency virus (HIV) 1, HIV 2, or hepatitis B surface antigen (HBsAg), or positive for anti-HIV 1, anti-HIV 2, or anti hepatitis C virus (HCV) antibodies at the Screening Visit.
History of alcohol or drug addiction during the year before the Screening Visit, or has a positive drug or alcohol screen at the Screening Visit or Check-in.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 2: 300 μg IW-3300	IW-3300	Dose 2: within the cohort, 6 participants receive active drug (IW-3300)
Cohort 1: Placebo	Placebo	Within the cohort, 2 participants will receive the matching placebo dose
Cohort 1: 100 μg IW-3300	IW-3300	Dose 1: within the cohort, 6 participants receive active drug (IW-3300)
Cohort 2: Placebo	Placebo	Within the cohort, 2 participants will receive the matching placebo dose
Cohort 3: Placebo	Placebo	Within the cohort, 2 participants will receive the matching placebo dose
Cohort 4: Placebo	Placebo	Within the cohort, 2 participants will receive the matching placebo dose
Cohort 3: 900 μg IW-3300	IW-3300	Dose 3: within the cohort, 6 participants receive active drug (IW-3300)
Cohort 4: 2500 μg IW-3300	IW-3300	Dose 4: within the cohort, 6 participants receive active drug (IW-3300)

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	From first dose of study drug through 24 hours post-Day 1 dose	An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a treatment-emergent AE (TEAE) if the AE started after initial study drug administration and within 1 day of the last dose of study drug.
Number of Participants With Serious TEAEs	From first dose of study drug through 24 hours post-Day 1 dose	A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; or other situations such as important medical events that may not be immediately life threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. An SAE was considered a treatment-emergent SAE (serious TEAE) if the SAE started after initial study drug administration and within 1 day of the last dose of study drug.

Secondary Outcome Measures